With the Trump administration preparing to take office, the Biosecure Act is in limbo. The bill, which would require U.S. companies to sever contracts with some Chinese manufacturing and research organizations, is now sitting in the hands of a lame-duck Congress.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,